Clinical Trial Update: Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of oral dalfampridine-SR for spasticity resulting from spinal cord injury has completed and posted results. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• Fampridine-Sustained Release (dalfampridine)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Spinal Cord Injury, Muscle Spasticity | Phase 3 | Status: COMPLETED | Results posted: 2014-02-05